相关实验视频
Updated: May 12, 2026

10:02
Use of Rabbit Eyes in Pharmacokinetic Studies of Intraocular Drugs
Published on: July 23, 2016
32.0K
对于糖尿病黄斑瘤的内法里西马布的现实世界疗效:系统性审查
Safiullah Nasimi1, Nasratullah Nasimi1, Jakob Grauslund1,2,3,4
1Department of Ophthalmology, Odense University Hospital, 5000 Odense, Denmark.
Journal of personalized medicine
|September 28, 2024
概括
针对糖尿病黄斑 (DME) 的新疗法法法里西马布 (Faricimab) 的疗效与现有疗法相美. 这种双特异性剂允许延长治疗间隔,减少患者在现实环境中的负担.
科学领域:
- 眼科医生 眼科 眼科
- 视网膜疾病 视网膜疾病
- 药理学 药理学是指药理学的学科.
背景情况:
- 糖尿病黄斑 (DME) 是导致视力丧失的主要原因.
- 抗血管内皮生长因子 (抗VEGF) 治疗是对DME的标准治疗方法.
- 法里西马布是一种新型双特异性药物,向VEGF和血管蛋白-2.
研究的目的:
- 系统地审查关于法里西马布在治疗DME的疗效的现实世界的证据.
- 为了评估视觉敏度和斑点厚度变化与法里西马布治疗.
- 评估延长治疗间隔的可行性.
主要方法:
- 在11个数据库中进行系统的文献搜索.
- 独立,重复的研究选择和数据提取.
- 对10项符合条件的研究进行定性审查,包括6054只眼睛.
主要成果:
- 法里西马布在最佳校正视敏度和减少黄斑厚度方面表现出改善.
- 在未接受过治疗的眼睛中,延长治疗间隔在61-81%,而在先前接受过治疗的眼睛中,延长治疗间隔在36-78%是可行的.
- 研究包括以前没有接受过治疗的DME患者和之前接受过治疗的DME患者.
结论:
- 费里西马布 (Faricimab) 的临床结果与已知的DME抗VEGF治疗方法相似.
- 法里西马布可以延长治疗间隔,从而可能减少患者的治疗负担.
- 建议进行进一步的长期实践研究来验证这些发现.
相关概念视频
Open Angle Glaucoma: Treatment
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...
Diabetic Retinopathy
DefinitionDiabetic retinopathy is a microvascular complication of diabetes affecting the retinal blood vessels.Risk FactorsDiabetic retinopathy is present in almost all individuals with type 1 diabetes and more than 60% of those with type 2 diabetes after two decades of disease.The risk increases with poor glycemic control, hypertension, dyslipidemia, smoking, pregnancy, and puberty.Although cataracts and glaucoma are also more frequent in people with diabetes, retinopathy remains the leading...

